Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
5
4
2022
Statut:
ppublish
Résumé
The study of plasma cell-free DNA integrity (cfDI) has shown potential for providing useful information in neoplastic patients. The aim of this study is to estimate the accuracy of an electrophoresis-based method for cfDI evaluation in the assessment of pathologic complete response (pCR) in patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT). Fifty-one patients with BC undergoing anthracycline-/taxane-based NACT were recruited. Plasma samples were collected from each patient at diagnosis (t0), after anthracycline administration (t1), and after NACT completion (t2). The concentration of differently sized cell-free DNA fragments was assessed by automated electrophoresis. cfDI, expressed as cfDI index, was calculated as the ratio of 321-1,000 bp sized fragment concentration to 150-220 bp sized fragment concentration assessed at t2. cfDI index was then used to build an exploratory classifier for BC response to NACT, directly comparing its sensitivity and specificity with magnetic resonance imaging (MRI), through bootstrapped logistic regression. cfDI index was assessed on 38 plasma samples collected from as many patients at t2, maintaining a 30/70 ratio between pCR and non-pCR patients. cfDI index showed an area under the receiver operating characteristic curve in predicting the achievement of pCR of 81.6, with a cutoff above 2.71 showing sensitivity = 81.8 and specificity = 81.5. The combination of cfDI index and MRI showed, in case of concordance, an area under the receiver operating characteristic curve of 92.6 with a predictive value of complete response of 87.5 and a predictive value of absence of complete response of 94.7. cfDI index measured after NACT completion shows great potential in the assessment of pCR in patients with BC. The evaluation of its use in combination with MRI is strongly warranted in prospective studies.
Identifiants
pubmed: 35201850
doi: 10.1200/PO.21.00198
pmc: PMC8974578
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2100198Références
Cytokine. 2008 Oct;44(1):65-9
pubmed: 18691902
Syst Rev. 2018 Jun 26;7(1):89
pubmed: 29945652
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
J Surg Oncol. 2019 Nov;120(6):903-910
pubmed: 31400007
Clin Chim Acta. 2013 Sep 23;424:222-30
pubmed: 23727028
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
Cancer Lett. 2006 Nov 8;243(1):64-70
pubmed: 16412565
Front Oncol. 2020 Feb 12;10:93
pubmed: 32117747
Breast Cancer Res Treat. 2014 Jul;146(1):163-74
pubmed: 24838941
Tumour Biol. 2016 Jun;37(6):7565-72
pubmed: 26684805
Medicine (Baltimore). 2018 Mar;97(13):e0197
pubmed: 29595655
Lab Med. 2014 Winter;45(1):6-11
pubmed: 24719978
J Clin Oncol. 2006 Sep 10;24(26):4270-6
pubmed: 16963729
Clin Chem. 2005 Apr;51(4):781-4
pubmed: 15708950
Radiology. 1990 Sep;176(3):593-606
pubmed: 2202008
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Cancers (Basel). 2021 Jul 10;13(14):
pubmed: 34298675
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
J Cancer Res Clin Oncol. 2013 Jun;139(6):995-1003
pubmed: 23479212
Cardiovasc Res. 2000 Feb;45(3):528-37
pubmed: 10728374
J Natl Compr Canc Netw. 2019 Aug 1;17(8):957-967
pubmed: 31390594
Breast Cancer Res. 2013;15(5):211
pubmed: 24090167
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
Transl Cancer Res. 2019 Aug;8(4):1531-1539
pubmed: 35116896
Pathol Res Pract. 2019 Jan;215(1):29-33
pubmed: 30501932
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Oncotarget. 2017 Apr 24;8(33):54537-54547
pubmed: 28903362
Arch Pathol Lab Med. 2017 Nov;141(11):1544-1557
pubmed: 28782984
J Am Coll Surg. 2017 Dec;225(6):740-746
pubmed: 28919579